|
(ÁÖ)´ë¾ÈÀÇ·á±â |
ôÃß°ßÀÎÀÇ·á±â ¿µ¾÷»ç¿ø¸ðÁý
¼¿ï ±¤Áø±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
11.19 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ) ³Ø½ºÆ®¼¿·º¼Ç |
Regulatory (RA) Team Leader (Non ¾à»ç )
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
12.03 |
|
|
M&C |
·¯½Ã¾Æ Å뿪 ¹× ¹ø¿ª
¼¿ï °³²±¸ | Çз¹«°ü |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.06 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
½ÅÈÀüÀÚ(ÁÖ) |
ÀÇ·á±â±â ´ã´çÀÚ, ÀÇ·á±â±â °³¹ß °æÇèÀÚ
¼¿ï °³²±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
07.20 |
|
|
ÀÌÁöÄÚ¾Æ |
ÀÇ·á±â±â ±¹³»¿Ü ÀÎÇã°¡ ¹× ÀÎÁõ, ÀÇ·á±â±âGMP µî RA ¾÷¹«
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.06 |
|
|
(ÁÖ) ³Ø½ºÆ®¼¿·º¼Ç |
E-health Technology Infrastructure Leader
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇÁ·Î±×·¡¸Ó(À¥,ÀÀ¿ë,½Ã½ºÅÛ) |
7³â¡è |
ä¿ë½Ã |
11.03 |
|
|
À̳ëºê·¹ÀÎ |
Senior Quality Standards Associate Ãʺù
¼¿ï °ºÏ±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
12.07 |
|
|
µå¸²¼Ö·ç¼Ç |
30³â ÀÇ·á±â±â¾÷ ¿¬±¸¼Ò SMPS,FW,¾Æ³¯·Î±×HW °³¹ß °æ·ÂÁ÷ Ãæ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
03.06 |
|
|
(ÁÖ)¾ÆÀÌ¿¥Æ¼¸ÞµðÄ® |
½ÉÇ÷°üÁ¶¿µ½Ç ¿µ¾÷»ç¿ø ¸ðÁý
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.30 |
|
|
À§´Ï´õ½ºÄÁ¼³Æà |
¿Ü±¹°è»ç ¸¶ÄÉÆà 2³âÀÌ»ó
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
10.10 |
|
|
(ÁÖ) ³×¿À ¿þÀ̺ê |
ÀÇ·á±â±â(¹Ì¿ëÀåºñ) ÆǸŠ»ç¿ø ¸ðÁý
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.20 |
|
|
Çѱ¹µ¹±â(ÁÖ) |
ÀÇ·á±â±â ¿µ¾÷Á÷ »ç¿øÀ» ¸ðÁýÇÕ´Ï´Ù.
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
12.05 |
|
|
(ÁÖ)ÄÚ¶÷·¦Å×Å© |
°Å·¡Ã³ °ü¸® Áö¿ø ¹× ¿µ¾÷, ¸¶ÄÉÆÃ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
11.10 |
|